Premium
Pharmacological evaluation of novel furan‐2‐carboxamide derivatives as antihyperlipidemic agents in triton‐induced rats (794.4)
Author(s) -
AlQirim Tareq,
Shattat Ghassan,
AbuSkeika Ghassan,
Alhusaini Nadeem
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.794.4
Subject(s) - hyperlipidemia , furan , chemistry , triglyceride , bezafibrate , carboxamide , in vivo , pharmacology , cholesterol , biochemistry , medicine , endocrinology , biology , organic chemistry , diabetes mellitus , microbiology and biotechnology
A new series of Furan‐2‐carboxamide derivatives of anthraquinone (compounds N 1 , N 3 , N 5 ) were synthesized and tested in vivo using Triton WR‐1339‐induced hyperlipidemic rat as an experimental model for their hypolipidemic activity. The tested animals were divided into six groups: control, hyperlipidemic, N1, N3, N5 and bezafibrate. The designed target derivatives, compounds N 1, N3 were inactive. Compound N 5 has shown a significant reduction in triglyceride level in rats by 66.5% after 18 h in comparison to the hyperlipidemic group. Furthermore, high‐density lipoprotein‐cholesterol levels were remarkably increased in compound N5 (p < 0.001) after 18 h in comparison to the hyperlipidemia group and also compound N5 significantly reduced LDL‐C level (p< 0.001) after 18 h in comparison to the hyperlipidemia group. Furthermore, the total cholesterol level was reduced by 85% after 18 h in compound N5 compared to HLG‐treated rats. The present study demonstrated new properties of novel series of furan‐2‐carboxamides N5 as a potent lipid‐lowering agent. It is therefore reasonable to assume that this compound may have a promising potential in the treatment of hyperlipidemia and coronary heart diseases. Grant Funding Source : This research is supported by Al‐Zaytoonah University of Jordan